YaoGeJu

YaoGeJuCDE public lists · weekly counts

National Drug-Review Weekly

The available CDE acceptance records list 342 drug applications between 13 November 2026 and 19 November 2026 (data as of 23 November 2026). Of these, generic applications numbered 57, covering 40 drug names.

2026/11/13 – 2026/11/19

Period
2026/11/13 to 2026/11/19, 7 days inclusive
Data as of
2026/11/23
Loaded records
95,213 acceptance records, 11,351 under review now
Source
Public data from the CDE acceptance list and under-review list
New acceptances this week
342
Drugs with new generic filings (by drug name, de-duplicated)
40
Accepted this week, now under review
342

DefinitionAcceptance numbers accepted this week that are still on CDE's under-review list at the data cut-off; counted by acceptance date.

Names with a public page are linked.

New acceptances this week

By application type and drug type

342filings, 57 of them generic

By application type

Application typeFilings
Supplement180
New drug66
Generic57
Import29
Import re-registration9
Unspecified1

By drug type

Drug typeFilings
Chemical drug187
TCM85
Therapeutic biologic61
Biologic5
Prophylactic biologic4

DefinitionAcceptance numbers whose acceptance date falls in this week; application type and drug type are the CDE list's own text, with empty values shown as “Unspecified”.

Most new generic filings, by drug

40 drugs with new generic filings; top 10 listed

#DrugNew generic filingsFiling companiesUnder review, all years
1司美格鲁肽注射液 · No verified English name5199
2Mirogabalin Besilate Tablets3264
3Ambroxol Hydrochloride Oral Solution3149
4Rosuvastatin Calcium and Ezetimibe Tablets (I)227
5Trazodone Hydrochloride Sustained-release Tablets2222
6二硫化硒洗剂 · No verified English name2116
7Brexpiprazole Orally Disintegrating Tablets2112
8恩那度司他片 · No verified English name212
9Topiramate Tablets212
10Sildenafil Citrate Tablets2114

DefinitionThis week's acceptance numbers with application type “Generic”, grouped by identical drug name; filing companies are de-duplicated by first applicant; under review, all years = acceptance numbers for that name, from any year, still on the CDE under-review list. Top 10 by filings, then companies.

Most new acceptances, by company

211 companies with new acceptances; top 10 listed

#Company (first applicant)FilingsDrugsGeneric
1Henan Pu Rui Pharma Co., Ltd. romanized1480
2Eli Lilly and Company940
3Novo Nordisk A/S610
4Boehringer Ingelheim International GmbH520
5Suzhou Te Rui Pharma Co., Ltd. romanized515
6Sichuan Sheng Tong Yuan Pharmaceutical Group Co., Ltd. romanized440
7Beijing Tong Ren Tang Co., Ltd. Tong Ren Tang Pharmaceutical Factory romanized420
8CSL Behring GmbH410
9Takeda Manufacturing Austria AG410
10Chengdu Di Ao Pharmaceutical Group Co., Ltd. romanized410

DefinitionThis week's acceptance numbers grouped by first applicant; drugs are de-duplicated by drug name; “Generic” counts filings with application type “Generic”. Top 10 by filings.

Under-review list changes

Based on changes in CDE's under-review list

Entered review this week
331
Left the under-review list this week
657

Of these, NMPA published approval-document delivery for 342 (including 338 supplemental applications, not counted as new marketing approvals) and notification delivery for 20; the outcome of the other 295 is to be checked.

Most filings leaving review, by company

Most filings leaving review, by company
#Company (first applicant)FilingsDrugs
1Bai Ji Shen Zhou (Suzhou) Bio Technology Co., Ltd. romanized133
2Mu Dan Jiang Ling Tai Pharma Co., Ltd. romanized99
3AbbVie Inc.81
4Luo Yang Yi Long Pharma Co., Ltd. romanized77
5Shaanxi Dong Tai Pharmaceutical Co., Ltd. romanized77
6Shijiazhuang No.4 Pharmaceutical Co., Ltd.76
7Eli Lilly and Company72
8Novartis Pharma AG64
9Guangdong Tai En Kang Pharmaceutical Factory Co., Ltd. romanized62
10Hybio Pharmaceutical Co.,Ltd.61

Most filings entering review, by company

Most filings entering review, by company
#Company (first applicant)FilingsDrugs
1Henan Pu Rui Pharma Co., Ltd. romanized148
2CISEN PHARMACEUTICAL CO., LTD.63
3Novo Nordisk A/S61
4Shandong Bu Zhang Pharmaceutical Co., Ltd. romanized55
5Boehringer Ingelheim International GmbH52
6Eli Lilly and Company52
7Beijing Tong Ren Tang Co., Ltd. Tong Ren Tang Pharmaceutical Factory romanized42
8Terumo Corporation Kofu Factory41
9Zhongshan Wanhan Pharmaceuticals Co., Ltd.41
10Shenzhen Shi Fan Gu Pharma Co., Ltd. romanized41

DefinitionEntered review = acceptance numbers first listed on CDE's under-review list this week, excluding numbers already listed on the record start date (2026/10/22). Left review = acceptance numbers last listed this week and no longer listed at the data cut-off; the outcome follows NMPA's approval-document delivery notices, and numbers without such a record are marked to be checked. Companies are counted by first applicant.

Class 3 and new-drug acceptances

105 this week

AcceptedDrugApplicants
2026/11/19Generic · Class 3 Colistimethate Sodium for InjectionCYHS2602859 Tianjin Chase Sun Pharmaceutical Co.,Ltd; Sichuan Huiyu Pharmaceutical Co., Ltd.
2026/11/19Generic · Class 3 司美格鲁肽注射液 · No verified English nameCYHS2602857 Suzhou Te Rui Pharma Co., Ltd. romanized; Shenzhen Shi Jian Xiang Biopharmaceutical Co., Ltd. romanized
2026/11/19Generic · Class 3 司美格鲁肽注射液 · No verified English nameCYHS2602856 Suzhou Te Rui Pharma Co., Ltd. romanized; Shenzhen Shi Jian Xiang Biopharmaceutical Co., Ltd. romanized
2026/11/19Generic · Class 3 司美格鲁肽注射液 · No verified English nameCYHS2602855 Suzhou Te Rui Pharma Co., Ltd. romanized; Shenzhen Shi Jian Xiang Biopharmaceutical Co., Ltd. romanized
Generic · Class 3 司美格鲁肽注射液 · No verified English name —
Generic · Class 3 司美格鲁肽注射液 · No verified English name —
2026/11/19Generic · Class 3 盐酸氨酮戊酸颗粒剂 · No verified English nameCYHS2602848 Shanghai Fu Dan Zhang Jiang Biopharmaceuticals Co., Ltd. romanized
2026/11/19New drug · Class 1 IBI363 · No verified English nameCXSL2601291 Xin Da Biopharmaceutical (Suzhou) Co., Ltd. romanized
2026/11/19New drug · Class 1 IBI363 · No verified English nameCXSL2601290 Xin Da Biopharmaceutical (Suzhou) Co., Ltd. romanized
2026/11/19New drug · Class 1 IBI3002 · No verified English nameCXSL2601289 Xin Da Biopharmaceutical (Suzhou) Co., Ltd. romanized
2026/11/19New drug · Class 1 GenSci161注射液 · No verified English nameCXSL2601288 Changchun Jin Sai Pharma Co., Ltd. romanized
2026/11/19New drug · Class 1 GenSci161注射液 · No verified English nameCXSL2601287 Changchun Jin Sai Pharma Co., Ltd. romanized
2026/11/19New drug · Class 1 注射用DB-1421 · No verified English nameCXSL2601286 Ying En Bio Technology (Shanghai) Co., Ltd. romanized
2026/11/19New drug · Class 1 注射用HCB303 · No verified English nameCXSL2601285 Shanghai Han Ke Bio Co., Ltd. romanized; Guangzhou Han Ke Bio Co., Ltd. romanized
2026/11/19New drug · Class 1 DA-A-493片 · No verified English nameCXHL2601456 Chengdu Di Ao Pharmaceutical Group Co., Ltd. romanized
2026/11/19New drug · Class 1 DA-A-493片 · No verified English nameCXHL2601455 Chengdu Di Ao Pharmaceutical Group Co., Ltd. romanized
2026/11/19New drug · Class 1 DA-A-493片 · No verified English nameCXHL2601454 Chengdu Di Ao Pharmaceutical Group Co., Ltd. romanized
New drug · Class 1 DA-A-493片 · No verified English name —
2026/11/18Generic · Class 3 二硫化硒洗剂 · No verified English nameCYHS2602839 Anhui Tai Du Biopharmaceuticals Technology Co., Ltd. romanized; Yu Song Yuan Pharma Co., Ltd. romanized
2026/11/18Generic · Class 3 二硫化硒洗剂 · No verified English nameCYHS2602838 Anhui Tai Du Biopharmaceuticals Technology Co., Ltd. romanized; Yu Song Yuan Pharma Co., Ltd. romanized
2026/11/18New drug · Class 1.1 龙藤颗粒 · No verified English nameCXZL2600116 Heilongjiang Sheng Ji Ren Pharma Co., Ltd. romanized
2026/11/18New drug · Class 1 格斯泮妥塔单抗注射液 · No verified English nameCXSS2600190 Ming Ji Biopharmaceutical (Beijing) Co., Ltd. romanized
2026/11/18New drug · Class 1 LET003注射液 · No verified English nameCXSL2601284 He Bo Pharmaceuticals (Shanghai) Co., Ltd. romanized
2026/11/18New drug · Class 2.4 注射用重组A型肉毒毒素 · No verified English nameCXSL2601283 Jiangsu Yao Hai Nuo Xin Bio Technology Co., Ltd. romanized; Yao Hai Nuo Xin Bio Technology (Wuhan) Co., Ltd. romanized
2026/11/18New drug · Class 1 注射用GB268 · No verified English nameCXSL2601282 Yi Teng Pharmaceuticals (Zhuhai) Co., Ltd. romanized
2026/11/18New drug · Class 1 ALC01细胞注射液 · No verified English nameCXSL2601281 Ai Kai Li Yuan Bio Technology (Shanghai) Co., Ltd. romanized
2026/11/18New drug · Class 2.3 EP-0170T(Ⅰ) · No verified English nameCXHS2600154 Chengdu Shuo De Pharma Co., Ltd. romanized
2026/11/18New drug · Class 1 TER-2013片 · No verified English nameCXHL2601452 Bai Ji Shen Zhou (Shanghai) Bio Technology Co., Ltd. romanized
2026/11/18New drug · Class 1 TER-2013片 · No verified English nameCXHL2601451 Bai Ji Shen Zhou (Shanghai) Bio Technology Co., Ltd. romanized
2026/11/18New drug · Class 1 BG-75202片 · No verified English nameCXHL2601450 Bai Ji Shen Zhou (Suzhou) Bio Technology Co., Ltd. romanized

75 more not listed (at most 30 rows).

For some entries, the drug or company page limits access to the acceptance date, filing number and applicants.

DefinitionThis week's acceptance numbers with application type “New drug”, or registration applications whose class starts with 1, 2 or 3 (supplements and re-registrations excluded); newest first, at most 30 rows.

Subscribe to the weekly

No account needed.

The email carries the same content as this page, in the language you subscribe in: section counts, top-10 lists and definitions, with a link to the full report. Your address is used only to send the report.

A text version of this report, weekly, in the language you subscribe in. You will receive one confirmation email first; sending starts only after you click its link. Every issue carries an unsubscribe link.